Longevity education

Stay curious about aging well — without pretending to be your clinician.

Read today's research headlines, run honest calculators, keep a private record, and assemble an educational supplement protocol. Not a clinic.

Today's news Open calculators Build your protocol

Wearables

Sync your wearables. Personalize your longevity plan.

Connect Apple Watch / Apple Health, Garmin, and other wearables (Oura, Whoop, Strava when enabled). We pull steps, sleep, and training into your private record so calculators and your protocol can use recent averages. Not medical advice.

Connect your wearable Create a member record

Today's news

All headlines →

ScienceDaily · 8 Sept 2026

Ozempic and Wegovy may have an unexpected mental health benefit

Study (observational). Griffith University researchers analyzing Swedish nationwide data on nearly 15,000 people with bipolar disorder who were prescribed GLP-1 medicines over 15 years report in Acta Psychiatrica Scandinavica that periods on semaglutide tracked with a 21% lower risk of psychiatric hospitalization. Liraglutide and dulaglutide did not show the same association. This is not a randomized trial and not a mood-disorder treatment claim. Semaglutide remains a prescription medicine for approved uses. Off-label psychiatric or longevity use is clinician-only. This is not medical advice and not a reason to start, stop, or replace any drug. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read at ScienceDaily →

study
longevity
research
glp1
off-label-context

ScienceDaily · 8 Sept 2026

Early statin use linked to 15% lower dementia risk

Study (observational). Using Danish registers of 132,585 people newly diagnosed with type 2 diabetes (2006–2019), Ternhamar and colleagues reported at ESC Congress 2026 and in The Lancet Regional Health – Europe that starting statins within a year of diagnosis associated with a 15% lower relative dementia risk over 10 years versus no statin; starting at 1–5 years associated with 10% lower risk. Median follow-up 7.1 years; 2.7% developed dementia. Clone-censor-weight methods emulate a trial but cannot prove causation. Statins are prescription cholesterol medicines, not a dementia cure or a supplement.

Read at ScienceDaily →

study
aging
cognition
research

ScienceDaily · 7 Sept 2026

Your gut microbiome may be more contagious than scientists thought

Study. University of Vienna researchers writing in Nature used reverse-ecology genomics on thousands of gut isolates and metagenomes. Familiar species split into adapted populations, some tracking with older age, IBD, colorectal cancer, and type 2 diabetes. Competitive lineages also appear to have spread across continents in decades. This is evolutionary mapping, not proof that you catch disease from a roommate and not a probiotic prescription. Diet, medicines, and contact may all shape which strains settle.

Read at ScienceDaily →